Surrozen (NASDAQ:SRZN) COO Charles Williams Sells 1,566 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) COO Charles Williams sold 1,566 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $19.87, for a total value of $31,116.42. Following the transaction, the chief operating officer directly owned 12,982 shares of the company’s stock, valued at approximately $257,952.34. This represents a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Surrozen Stock Performance

Shares of NASDAQ SRZN opened at $19.67 on Wednesday. The stock’s 50-day simple moving average is $17.64 and its 200-day simple moving average is $13.39. The firm has a market capitalization of $168.57 million, a PE ratio of -0.88 and a beta of 0.58. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $24.94.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The company had revenue of $0.98 million during the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. On average, sell-side analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Wall Street Zen raised Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Lifesci Capital raised Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC lifted its holdings in shares of Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the period. Geode Capital Management LLC increased its stake in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after buying an additional 5,702 shares during the period. Woodline Partners LP purchased a new position in Surrozen during the 3rd quarter worth $621,000. Armistice Capital LLC acquired a new stake in shares of Surrozen in the 2nd quarter worth $536,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Surrozen in the 3rd quarter worth $889,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.